Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
349,9 EUR | +0,20% | +0,14% | +1,86% |
24/04 | Bel20 levert winsten toch in | AM |
24/04 | Melexis primus op groene beurs | AM |
Vakgebied
Aantal werknemers: 1 148
Verkoop per activiteit
EUR in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Antibody-based Medicines
100,0
%
| 391 | 100,0 % | 1 134 | 100,0 % | +190,23% |
Verkoop per regio
EUR in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
87,8
%
| 359 | 91,9 % | 996 | 87,8 % | +177,12% |
EMEA
5,9
%
| - | - | 67 | 5,9 % | - |
Japan
4,6
%
| 15 | 3,8 % | 52 | 4,6 % | +248,00% |
China
1,7
%
| 4 | 1,0 % | 19 | 1,7 % | +368,86% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Founder | 52 | 01-01-08 | |
Karl Gubitz
DFI | Director of Finance/CFO | 54 | 01-06-21 |
Filip Borgions
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-15 |
Karen Massey
COO | Chief Operating Officer | 45 | 13-03-23 |
Peter Ulrichts
CTO | Chief Tech/Sci/R&D Officer | 44 | 01-01-23 |
Luc Truyen
CTO | Chief Tech/Sci/R&D Officer | 59 | 01-04-22 |
Beth Delgiacco
IRC | Investor Relations Contact | - | 01-01-18 |
General Counsel | 54 | 14-02-22 | |
Marc Schorpion
HRO | Human Resources Officer | 66 | 01-12-18 |
Arjen Lemmen
PRN | Corporate Officer/Principal | 39 | 01-01-16 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 71 | 26-04-17 | |
Joseph deBethizy
BRD | Director/Board Member | 74 | 13-05-15 |
Pamela Klein
BRD | Director/Board Member | 63 | 28-04-16 |
Chairman | 66 | 15-10-08 | |
Founder | 52 | 01-01-08 | |
James Daly
BRD | Director/Board Member | 63 | 08-05-18 |
Steve Krognes
BRD | Director/Board Member | 56 | 27-02-23 |
Camilla Sylvest
BRD | Director/Board Member | 52 | 08-09-22 |
Ana Cespedes
BRD | Director/Board Member | 51 | 12-12-22 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 59 431 079 | 59 358 579 ( 99,88 %) | 0 | 99,88 % |
Bedrijfsgegevens
Bedrijven van de groep
Naam | Categorie en sector |
---|---|
arGEN-X BV
arGEN-X BV Pharmaceuticals: OtherHealth Technology Part of argenx SE, arGEN-X BV is a Belgian company that manufactures antibody-based medicines. The private company is based in Zwijnaarde, Belgium. |
Pharmaceuticals: Other
|
Sector
Verkoop per regio
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+1,86% | 22,19 mld. | |
-1,51% | 105 mld. | |
+3,22% | 97,5 mld. | |
-16,53% | 21,33 mld. | |
-8,49% | 18,68 mld. | |
-42,33% | 16,6 mld. | |
-20,09% | 14,52 mld. | |
+5,47% | 14,09 mld. | |
+28,85% | 10,99 mld. | |
-24,93% | 8,63 mld. |
- Beurs
- Aandelen
- Koers ARGX
- Onderneming argenx SE